Price T Rowe Associates Inc X4 Pharmaceuticals, Inc Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in X4 Pharmaceuticals, Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 50,226 shares of XFOR stock, worth $31,642. This represents 0.0% of its overall portfolio holdings.
Number of Shares
50,226
Previous 39,307
27.78%
Holding current value
$31,642
Previous $55,000
45.45%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding XFOR
# of Institutions
108Shares Held
102MCall Options Held
418KPut Options Held
71.7K-
Bain Capital Life Sciences Investors, LLC Boston, MA16.9MShares$10.7 Million2.01% of portfolio
-
Nea Management Company, LLC Timonium, MD15MShares$9.44 Million0.82% of portfolio
-
Black Rock Inc. New York, NY10.7MShares$6.73 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.29MShares$5.22 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA7.13MShares$4.49 Million0.1% of portfolio
About X4 Pharmaceuticals, Inc
- Ticker XFOR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,646,096
- Market Cap $43.2M
- Description
- X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...